Gilead Sciences (NASDAQ:GILD) Price Target Raised to $150.00 at BMO Capital Markets

Gilead Sciences (NASDAQ:GILD) had its price objective increased by equities research analysts at BMO Capital Markets from $135.00 to $150.00 in a research note issued to investors on Monday,MarketScreener reports. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ target price would indicate a potential upside of 10.35% from the stock’s current price.

Several other analysts have also recently commented on GILD. Argus increased their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. Scotiabank initiated coverage on Gilead Sciences in a report on Thursday, November 13th. They set a “sector outperform” rating and a $140.00 price objective on the stock. Rothschild & Co Redburn increased their price objective on Gilead Sciences from $153.00 to $159.00 and gave the company a “buy” rating in a research report on Tuesday, January 20th. Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a research note on Thursday. Finally, Morgan Stanley cut their price target on Gilead Sciences from $151.00 to $150.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 13th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $134.12.

Gilead Sciences Stock Performance

Shares of NASDAQ:GILD opened at $135.93 on Monday. The business has a fifty day moving average of $123.98 and a 200-day moving average of $118.71. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. Gilead Sciences has a twelve month low of $92.26 and a twelve month high of $136.30. The firm has a market cap of $168.65 billion, a PE ratio of 21.07, a price-to-earnings-growth ratio of 0.71 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.16 by $0.31. The business had revenue of $7.77 billion for the quarter, compared to the consensus estimate of $7.42 billion. Gilead Sciences had a net margin of 27.88% and a return on equity of 51.86%. The firm’s quarterly revenue was up 3.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, equities research analysts predict that Gilead Sciences will post 7.95 EPS for the current fiscal year.

Insider Activity at Gilead Sciences

In other news, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction dated Friday, November 28th. The stock was sold at an average price of $125.08, for a total value of $625,400.00. Following the completion of the sale, the director directly owned 8,920 shares of the company’s stock, valued at $1,115,713.60. This represents a 35.92% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Andrew D. Dickinson sold 3,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $122.00, for a total transaction of $366,000.00. Following the transaction, the chief financial officer directly owned 153,503 shares in the company, valued at $18,727,366. The trade was a 1.92% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 141,757 shares of company stock worth $17,569,112. 0.27% of the stock is owned by company insiders.

Institutional Trading of Gilead Sciences

A number of large investors have recently made changes to their positions in the company. Brighton Jones LLC raised its stake in shares of Gilead Sciences by 20.6% in the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after purchasing an additional 2,450 shares during the period. Bison Wealth LLC bought a new position in shares of Gilead Sciences during the fourth quarter worth about $215,000. Sivia Capital Partners LLC raised its position in Gilead Sciences by 16.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock valued at $464,000 after buying an additional 602 shares during the last quarter. Patton Fund Management Inc. bought a new stake in Gilead Sciences in the 2nd quarter valued at approximately $237,000. Finally, Avior Wealth Management LLC boosted its position in Gilead Sciences by 57.2% during the 2nd quarter. Avior Wealth Management LLC now owns 7,530 shares of the biopharmaceutical company’s stock worth $790,000 after acquiring an additional 2,739 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.